|Title||Biological Age Acceleration and Motoric Cognitive Risk Syndrome.|
|Publication Type||Journal Article|
|Year of Publication||2023|
|Authors||Sathyan, S, Ayers, E, Adhikari, D, Gao, T, Milman, S, Barzilai, N, Verghese, J|
|Keywords||Motoric Cognitive Risk Syndrome|
OBJECTIVE: Motoric cognitive risk (MCR) syndrome, a predementia syndrome characterized by slow gait and subjective cognitive concerns, is associated with multiple age-related risk factors. We hypothesized that MCR is associated with biological age acceleration. We examined the associations of biological age acceleration with MCR, and mortality risk in MCR cases.
METHODS: Biological age was determined using proteomic and epigenetic clocks in participants aged 65 years and older in the LonGenity study (N = 700, females = 57.9%) and Health and Retirement Study (HRS; N = 1,043, females = 57.1%) cohorts. Age acceleration (AgeAccel) was operationally defined as the residual from regressing predicted biological age (from both clocks separately) on chronological age. Association of AgeAccel with incident MCR in the overall sample as well as with mortality risk in MCR cases was examined using Cox models and reported as hazard ratios (HRs).
RESULTS: AgeAccel scores derived from a proteomic clock were associated with prevalent MCR (odds ratio adjusted for age, gender, education years, and chronic illnesses [aOR] = 1.36, 95% confidence interval [CI] = 1.09-1.71) as well as predicted incident MCR (HR = 1.19, 95% CI = 1.00-1.41) in the LonGenity cohort. In HRS, the association of AgeAccel using an epigenetic clock with prevalent MCR was confirmed (aOR = 1.47, 95% CI = 1.16-1.85). Participants with MCR and accelerated aging (positive AgeAccel score) were at the highest risk for mortality in both LonGenity (HR = 3.38, 95% CI = 2.01-5.69) and HRS (HR = 2.47, 95% CI = 1.20-5.10).
INTERPRETATION: Accelerated aging predicts risk for MCR, and is associated with higher mortality in MCR patients. ANN NEUROL 2023.
|Grant List||R01AG057548(JV) / AG / NIA NIH HHS / United States |
R56AG044829(SM) / AG / NIA NIH HHS / United States
R56AG044829(JV) / AG / NIA NIH HHS / United States
P01AG021654(NB) / AG / NIA NIH HHS / United States
R01AG046949(NB) / AG / NIA NIH HHS / United States
R01AG057909(SM) / AG / NIA NIH HHS / United States
R01AG061155(SM) / AG / NIA NIH HHS / United States